Herein, we conducted a prospective study to investigate whether IL‐6, PCT, and CRP can be used to evaluate initial antibiotic efficacy of FN patients with hematological disorder through observing the early kinetic changes in these three biomarkers. This evidence concerns the gene IL6 and hematologic disorder.